Jason Park, CEO of Empress Therapeutics and Flagship Pioneering Operating Partner, shares the latest on Empress’ growing pipeline, the role partnering will play in applying the company’s Chemilogics platform across multiple disease areas, and why the company’s approach to sourcing chemistry from inside the human body can speed the development of safe and effective medicines. More from Flagship @ JPM2025 here.
Related Companies
- Empress Therapeutics Founded: 2020
